Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer.

Journal Article (Journal Article;Review)

Chronic kidney disease is prevalent, affecting more than one in ten adults. In this population, metabolic acidosis is considered a key underlying pathophysiological feature, tying together bone mineral disorders, sarcopenia, insulin resistance, vascular calcification, pro-inflammatory and pro-thrombotic states. This review aims to address the paucity of literature on alkalinizing agents, a promising treatment option that has known adverse effects.

Full Text

Duke Authors

Cited Authors

  • Copur, S; Sag, AA; Afsar, B; Rossignol, P; Covic, A; Kanbay, M

Published Date

  • December 2020

Published In

Volume / Issue

  • 52 / 12

Start / End Page

  • 2311 - 2320

PubMed ID

  • 32661618

Electronic International Standard Serial Number (EISSN)

  • 1573-2584

Digital Object Identifier (DOI)

  • 10.1007/s11255-020-02563-2


  • eng

Conference Location

  • Netherlands